13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-09-04 Event 2026-09-02 SEC 0001104659-26-105480 →

Dyer Timothy Mark Addex Therapeutics Ltd. ADXN

Stake: 9.01% Shares: 19,165,714 CUSIP: 00654J206 Class: American Depositary Shares, each representing 120 ordinary shares Ordinary shares

Item 4 — Purpose of Transaction

The Reporting Person acquired the securities of the Issuer at founding, through the exercise of options, acquisitions through participation in private placements and in consideration for his services as Chief Executive Officer of the Issuer. The reporting person also received shares issuable upon exercise of options. The terms of the Reporting Person's employment arrangements for 2025 were set forth in the Issuer's Annual Report on Form 20-F for such period filed by the Issuer with the Securities and Exchange Commission on May 15, 2026. Except in respect of such employment arrangements as set forth therein, the Reporting Person does not have any present plans which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) any action similar to any of those enumerated above. However, the Reporting Person reserves the right to change its plans at any time, as it deems appropriate, in light of its ongoing evaluation of (i) its business and liquidity objectives; (ii) the Issuer's financial condition, business, operations, competitive position, prospects and/or Share price; (iii) industry, economic and/or securities markets conditions; (iv) alternative investment opportunities; and (v) other relevant factors.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
7 13D/G filings on this issuer
6 other filings besides this one
Filer Track Record
5 filings by this filer
4 other filings in the data moat
Short Interest · settle 2026-08-14
DTC 8.35
7,083 shares short · +70.5% vs prior

Other 13D/G Filings on Addex Therapeutics Ltd.

FiledFormFilerStakeShares
2026-08-27 SCHEDULE 13D/A Dyer Timothy Mark 8.98% 19,095,510 view →
2023-04-05 SC Dyer Timothy Mark view →
2022-11-28 SC Growth Equity Opportunities Fund IV, LLC view →
2022-08-05 SC Dyer Timothy Mark view →
2022-01-10 SC Growth Equity Opportunities Fund IV, LLC view →
2021-09-08 SC Dyer Timothy Mark view →

Other Filings by Dyer Timothy Mark

FiledFormIssuerStakeShares
2026-08-27 SCHEDULE 13D/A Addex Therapeutics Ltd. 8.98% 19,095,510 view →
2023-04-05 SC Addex Therapeutics Ltd. ADXN view →
2022-08-05 SC Addex Therapeutics Ltd. ADXN view →
2021-09-08 SC Addex Therapeutics Ltd. ADXN view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →